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ABSTRACT
Introduction: Oral formulations of
5-aminosalicylic acid (5-ASA) for treatment of
ulcerative colitis have been developed to
minimize absorption prior to the drug reaching
the colon. In this study, we investigate the
release of 5-ASA from available oral mesalamine
formulations in physiologically relevant pH
conditions.
Methods: Release of 5-ASA from 6 mesalamine
formulations (APRISO, Salix Pharmaceuticals,
Inc., USA; ASACOL MR, Procter & Gamble
Pharmaceuticals UK Ltd.; ASACOL HD, Procter
& Gamble Pharmaceuticals, USA; MEZAVANT
XL, Shire US Inc.; PENTASA, Ferring
Pharmaceuticals, Ltd., UK; SALOFALK, Dr.
Falk Pharma UK Ltd.) was evaluated using
United States Pharmacopeia apparatus I and II
at pH values of 1.0 (2 h), 6.0 (1 h), and 6.8 (8 h).
Dissolution profiles were determined for each
formulation, respectively.
Results: Of the tested formulations, only the
PENTASA formulation demonstrated release of
5-ASA at pH 1.0 (48%), with 56% cumulative
release after exposure to pH 6.0 and 92% 5-ASA
release after 6–8 h at pH 6.8. No other
mesalamine formulation showed [1% drug
release at pH 1.0. The APRISO formulation
revealed 36% 5-ASA release at pH 6.0, with
100% release after 3 h at pH 6.8. The SALOFALK
formulation revealed 11% 5-ASA release at pH
6.0, with 100% release after 1 h at pH 6.8. No
5-ASA was released by the ASACOL MR,
ASACOL HD, and MEZAVANT XL
formulations at pH 6.0. At pH 6.8, the
ASACOL MR and ASACOL HD formulations
exhibited complete release of 5-ASA after 4 and
2 h, respectively, and the MEZAVANT XL
formulation demonstrated complete 5-ASA
release over 6–7 h.
Conclusion: 5-Aminosalicylic acid release
profiles were variable among various
commercially available formulations.
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Ulcerative colitis (UC) is a chronic mucosal
inflammatory condition that can affect any part
of the colon, and is characterized by periods of
remission and active disease associated with
symptoms of abdominal pain, diarrhea, rectal
bleeding, and fecal urgency [1, 2]. While the
complete etiology of UC remains unclear, risk
factors include genetic predisposition, history
of bacterial infections, and lifestyle factors [1].
Approximately 50% of patients with quiescent
UC may relapse within a given year [3],
highlighting the importance of treatments
that enable effective management of the
disease.
Mesalamine (5-aminosalicylic acid [5-ASA]),
a locally acting, anti-inflammatory compound
that reduces inflammation of the colonic
mucosa, is recommended first-line treatment
for patients with mild-to-moderate UC [4–6].
Available in both oral and topical formulations,
5-ASA is generally well tolerated and has proven
to be effective in symptom improvement as well
as in the induction and maintenance of UC
remission [5, 7–10]. For 5-ASA to be effective in
treating mild-to-moderate UC, the drug must be
able to directly target themucosa of the terminal
ileum and colon, where it negatively regulates
cyclooxygenase and lipoxygenase pathways to
prevent formation of prostaglandin and
leukotrienes [11], and increases the expression
of peroxisome proliferator-activated receptors
[12]. Immediate-release oral mesalamine
formulations result in the quick absorption of
5-ASA in the upper gastrointestinal (GI) tract,
with systemically absorbed drug having little
clinical effect [13, 14]. Therefore, some
controlled-release oral formulations of
mesalamine have been developed to control or
delay the release of the active 5-ASA to provide
stable delivery of 5-ASA to the colon [13, 15–18].
Many of these controlled-release
formulations are pH dependent, with enteric
coatings, and developed on the understanding
that the pH gradient of the human GI tract
progressively increases from the stomach
(approximately pH 2) to the small intestine
(approximately pH 6) to the colon (pH 7–8)
[19]. The enteric coatings of these formulations
were designed to resist the highly acidic
environment of the stomach and dissolve in
the more basic environment of the terminal
ileum (around pH 7). However, consistent
release of 5-ASA from pH-dependent
formulations may be hindered by fluctuations
of intestinal pH levels in patients with UC, in
whom colonic pH levels have been measured at
lower than pH 7 due to a variety of factors,
including reduced mucosal bicarbonate
secretion, increased mucosal and bacterial
lactate production, and impaired absorption
and metabolism of short-chain fatty acids [19,
20]. In addition, considerable tablet-to-tablet
variability in dissolution has been observed for
one pH-dependent release formulation
(ASACOL; Procter & Gamble Pharmaceuticals
UK Ltd., Surrey, UK) at pH\7 [21]. Therefore, in
patients with UC, release of 5-ASA may be
inconsistent and unpredictable from some oral
mesalamine formulations.
While previous studies have examined the
dissolution profiles of individual mesalamine
formulations, to date there has been no
comparative study that has examined the
dissolution profiles of various currently
available controlled-release mesalamine
formulations. To directly address this question,
we examined 5-ASA release at physiologically
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relevant pH values from 6 mesalamine
formulations: APRISO extended-release
capsules (Salix Pharmaceuticals, Inc., Raleigh,
NC, USA); ASACOL MR tablets (Procter &
Gamble Pharmaceuticals UK Ltd., Surrey, UK);
ASACOL HD tablets (Procter & Gamble
Pharmaceuticals, Cincinnati, OH, USA);
MEZAVANT XL tablets (Shire US Inc., Wayne,
PA, USA); PENTASA tablets (Ferring
Pharmaceuticals, Ltd., West Drayton, UK); and
SALOFALK tablets (Dr. Falk Pharma UK Ltd.,
Bourne End, UK).
METHODS
Dissolution experiments were conducted with
the following mesalamine formulations:
APRISO 0.375-g capsules; ASACOL MR 800-mg
tablets; ASACOL HD 800-mg tablets;
MEZAVANT XL 1.2-g tablets; PENTASA 500-mg
tablets; and SALOFALK 250-mg tablets. All drug
products used in the study were the
commercially available formulations. With the
exception of MEZAVANT XL, all the
mesalamine formulations were sourced from
retail outlets, and dissolution data were
collected on 6 units (tablets or capsules) of
each; the European Pharmacopoeia and the
United States Pharmacopeia (USP) minimum
requirement for dissolution testing is 6 dosage
units. For MEZAVANT XL, tablets were sourced
directly from Shire, the product’s manufacturer,
who provided the dissolution data on 12 dosage
units. USP apparatus I (basket) was used for the
APRISO capsules, while USP apparatus II was
used for all other tablet formulations (Sotax
AT7TM dissolution tester; Sotax Corporation,
Horsham, PA, USA) [22]. The USP apparatus
type was selected as such to permit placement
of the respective drug forms (capsule or tablet)
into the dissolution media for the duration of
the test without interfering with the ability to
observe them.
To investigate the effect of simulated GI
conditions on release of active 5-ASA,
dissolution testing was performed in 3 stages.
An initial acid stage (2 h at pH 1.0) was followed
by a 2-part buffer stage (1 h at pH 6.0 followed
by 8 h at pH 6.8; Table 1). The dissolution bath
was maintained at a mean (±standard deviation
[SD]) temperature of 37 C (±5 C), and the
quantitative determination of the amount of
Table 1 Experimental conditions used to study 5-ASA
release from mesalamine (USP apparatus I and II)
Stage Experimental conditions
Acid stage
Dissolution media 500 mL, HCl 0.1 N
pH 1–1.2
Incubation time, h 2
Sample time, h 0.5
Rotation speed, rpm 50
Buffer stage 1
Dissolution media 900 mL, 0.16 M phosphate buffer
pH 6.0
Incubation time, h 1
Sample time, h 1
Rotation speed, rpm 100
Buffer stage 2
Dissolution media 900 mL, 0.16 M phosphate buffer
pH 6.8
Incubation time, h 8
Sample time, h 0.5
Rotation speed, rpm 100
USP I method was used with APRISO capsules; USP II
was used with all other tablet formulations
5-ASA 5-aminosalicylic acid, USP United States
Pharmacopeia
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5-ASA released was measured by ultraviolet
visible (UV–Vis) spectrophotometry at
wavelengths of 301 nm at pH 1.0, and 330 nm
for both pH 6.0 and 6.8 (PerkinElmer Lambda
25TM; PerkinElmer Life and Analytical Sciences,
Inc., Waltham, MA, USA). The proportion of
5-ASA dose released was calculated as a mean
value of all units at each time point for each
formulation. While all drug products are
theoretically formulated to contain 100% of
the labeled active concentrations, differences
may occur in measured or reported
concentrations due to the variability
introduced by manufacturing or by analytical
methods. The USP allows for a range of
90–110% of the labeled drug content.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
RESULTS
The dissolution profiles of all tested mesalamine
formulations are shown in Fig. 1. The APRISO
formulation demonstrated consistent release of
5-ASA across individual capsules at each pH (see
Table 2 for SDs at pH 6.8). After 2 h at pH 1.0, 1%






















































































































































































































































































































































































































Fig. 1 Dissolution of 5-ASA formulations in simulated
gastrointestinal pH ranges. *n = 12 for MEZAVANT XL;
n = 6 for all other formulations. 5-ASA 5-aminosalicylic
acid
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was released after a subsequent hour at pH 6.0,
and the remaining drug was released over 3 h at
pH 6.8, with 73% of 5-ASA being released after
1 h at pH 6.8. For the ASACOL MR formulation,
no drug was released at either pH 1.0 or 6.0;
however, 100% of 5-ASA was released on average
after about 4 h of exposure to pH 6.8, with 35%
and 63% of 5-ASA release being observed after 1
and 2 h at pH 6.8. Considerable variability
between individual tablets in their release
characteristics was observed in the minimum
and maximum drug release profiles over time;
some tablets did not release 100% of drug until
about 7 h at pH 6.8. Like the ASACOL MR
formulation, the ASACOL HD formulation
demonstrated no drug release at either pH 1.0
or 6.0, but 100% of 5-ASA was released from all
tablets after about 2 h at pH 6.8, with 65% of
5-ASA release being observed after 1 h at pH 6.8.
Some tablet-to-tablet variability in 5-ASA release
was observed with the ASACOL HD formulation.
The MEZAVANT XL formulation also
exhibited no drug release at pH 1.0 and 6.0,
and 5-ASA release occurred over 6 h at pH 6.8;
after 3 h at pH 6.8, approximately 33% of 5-ASA
had been released, and after 5 h, about 75% of
5-ASA had been released. Dissolution behavior
was similar across tablets. Unlike the other
tested formulations, the dissolution profile
from the PENTASA formulation did not appear
to be pH sensitive and, therefore, demonstrated
pH-independent release of 5-ASA. Continuous
release of 5-ASA was observed with the
PENTASA formulation at each pH: at pH 1.0,
48% of the drug was released in 2 h; after an
additional hour at pH 6.0, a cumulative
amount of 56% was released; at pH 6.8, 70%
and 85% of 5-ASA had been released after 1 and
3 h, respectively, with a mean maximum
release of 92% achieved after 8 h. The
PENTASA formulation also demonstrated
consistent release of 5-ASA across individual
tablets. Lastly, the SALOFALK formulation
demonstrated no drug release at pH 1.0, 11%
release at pH 6.0, and complete drug release
within 1 h of exposure at pH 6.8. Similar 5-ASA
release profiles were observed across individual
SALOFALK tablets.
DISCUSSION
As the pH profile in the colon can vary in
patients with UC, with pH\7.0 reported in
some cases, non-homogenous release of 5-ASA
for enteric-coated, pH-dependent formulations
may occur [19, 23–25]. In the current study, the
dissolution rates of different mesalamine
formulations were compared at pH 6.8. Results
revealed a high degree of variation in release
profiles across different formulations.
All tested mesalamine formulations, except
for the PENTASA formulation, had little to no
release of 5-ASA at pH 1.0, while varying degrees
of 5-ASA release were observed at pH 6.0 and pH
6.8. The PENTASA formulation released 5-ASA
in a manner independent of pH level, with
steady continuous release over time. In general,
the enteric coatings of the other tested
formulations were designed to dissolve at
higher pH levels, such as those typically
observed in the lower sections of the GI tract.
After 1 h at pH 6.0, the APRISO formulation
released more than one-third of its active 5-ASA.
Both the ASACOL MR and ASACOL HD
formulations did not release the active drug at
pH 6.0; 3 of 6 tested ASACOL MR tablets did not
release any drug for the first hour at pH 6.8,
while drug release across ASACOL HD tablets at
pH 6.8 was more consistent. In a prior study by
Spencer et al. [21], release of 5-ASA from the
ASACOL 400-mg tablets at pH\7.0 exhibited
considerable variability from tablet to tablet,
though more consistent release was observed at
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pH 7.2. In that study, USP apparatus II was used
to test dissolution of the ASACOL tablet in a
similarly staged acid and buffer procedure: 2 h
at pH 1.2 stirring at 50 rpm, 1 h at pH 6.0
stirring at 100 rpm, and finally 1.5 h at either
pH 6.5, 6.8, or 7.2 stirring at 50 rpm. While
100% of 5-ASA was released from the ASACOL
tablets within 2 h at pH 7.2, complete release of
5-ASA was observed after 5 h at pH 6.8, whereas
only approximately 50% of 5-ASA was released
after 6 h at pH 6.5. Although it was postulated
that differences in tablet film-coat thickness
could account for the variability in 5-ASA
release from the tablets, a direct correlation
between film-coat thickness and dissolution
performance could not be made [21]. It should
be noted that the ASACOL 400-mg tablets
examined by Spencer et al. [21] are no longer
commercially available, and differ from the
ASACOL HD 800-mg and the ASACOL MR
800-mg formulations currently investigated.
The current study demonstrated complete
release of 5-ASA from the ASACOL tablets
within 2 h (ASACOL HD formulation) to 4 h
(ASACOL MR formulation) at pH 6.8, with high
tablet-to-tablet variability observed in the latter.
Without additional insight into the
formulation or manufacturing process for
either ASACOL HD or ASACOL MR, it remains
unclear why the dissolution profiles of these
two formulations differed from one other.
In contrast to the ASACOL MR formulation,
5-ASA release from other formulations
(PENTASA, APRISO, MEZAVANT XL, and
SALOFALK) was found to be relatively
consistent between tablets at pH 6.8. The
MEZAVANT XL formulation did not release
any drug at pH 6.0, but exhibited complete
drug release within 6–7 h at pH 6.8. Another
study examining the release profile of 5-ASA
from the MEZAVANT XL formulation [26] also
revealed minimal tablet-to-tablet variation, and
this observation was associated with consistent
film-coat thickness among the tablets
examined. Finally, the SALOFALK tablets
released 11% of 5-ASA at pH 6.0, then
exhibited rapid release of the remainder of its
5-ASA in less than 1 h at pH 6.8.
Results from D’Inca and colleagues [27]
showed that mesalamine formulations with
pH-dependent release achieved significantly
higher mucosal concentrations of 5-ASA
within the diseased colon in patients with UC
compared with time-dependent mesalamine
release formulations or pro-drugs. However, it
remains unclear whether the current study
findings regarding variability of release in vitro
have an effect in vivo. Thus, the clinical
relevance of these findings remains to be
elucidated.
CONCLUSIONS
In summary, significant variations were
observed between the dissolution profiles of 6
mesalamine formulations examined at a range
of pH values, with a few formulations also
exhibiting wide tablet-to-tablet variation in the
release of 5-ASA. However, it is still not known
whether a correlation exists between the
in vitro dissolution profiles of these
formulations and their release characteristics
in the colon. Additional studies will be needed
to determine if these findings are clinically
relevant.
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